dolutegravir: Clinical Trials

47 trials of dolutegravir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

24 completed, 8 recruiting, 5 terminated, 5 unknown. 47 Phase 2, 7 Phase 1, 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 247Completed 24, Recruiting 8, Terminated 5, Unknown 5, Active not recruiting 2, Withdrawn 2, Not yet recruiting 1
Phase 17Recruiting 3, Completed 2, Active not recruiting 1, Unknown 1
Phase 35Completed 3, Active not recruiting 1, Withdrawn 1

Follow dolutegravir: new trials by email Literature Review of dolutegravir trials Research Report on dolutegravir

Trials (filtered) newest first · largest first

All 47 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
Rifapentine, Isoniazid, Dolutegravir - Tuberculosis
Phase 1 / Phase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)1442026-09-282026-11-02
Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study
Dolutegravir (DTG) AND Tenofovir alafenamide (TAF), Tenofovir Disoproxil Fumarate, Dolutegravir - Healthy Volunteer, Weight Gain
Phase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)1202026-09-242026-11-16
Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Antiretrovirals
Maraviroc, Dolutegravir, Dendritic Cell Vaccine - Hiv, HIV I Infection
Phase 2RecruitingFederal University of São Paulo702026-07-152026-08-19
Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection
Combination of Dolutegravir + Tenofovir DF for treatment of HTLV-1 infection, Dolutegravir (DTG) - HTLV-1 Infection, HTLV I Associated Myelopathies
Phase 2RecruitingCarlos Brites1462026-05-072026-06-02
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC) - HIV Infections
Phase 2RecruitingViiV Healthcare1862026-02-112026-11-12
Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully
Doravirine 100Mg Tab and Lamivudine 300 Mg Tab, Dolutegravir 50mg Tab and Lamivudine 300 Mg Tab - HIV-1-infection
Phase 2RecruitingCentre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida4082025-04-302025-06-11
Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses
TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI, Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR) - HIV Infections, HBV Coinfection
Phase 2Not yet recruitingANRS, Emerging Infectious Diseases1402025-02-012025-02-05
UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children
dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen, Dolutegravir (DTG)/ Emtricitabine (FTC)/tenofovir alafenamide (TAF) - HIV Infection
Phase 2CompletedPENTA Foundation532024-12-112026-03-04
Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis
Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC, DTG 50 mg orally QD plus TDF/3TC, 2HPZM - HIV-associated Tuberculosis
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)302024-02-132026-07-20
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
Dolutegravir/Rilpivirine FDC - HIV Infections
Phase 1 / Phase 2RecruitingViiV Healthcare202023-07-062024-09-19
Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)
Dolutegravir, 3HP - Tuberculosis, HIV
Phase 1 / Phase 2Active not recruitingThe Aurum Institute NPC922023-05-242025-12-12
Pharmacokinetics and Safety of DolutegravIr in Neonate
Dolutegravir - Hiv
Phase 1 / Phase 2UnknownDesmond Tutu TB Centre562022-09-122023-12-18
DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old
Dolutegravir (DTG) and lamivudine (3TC), SOC - HIV Infections
Phase 2 / Phase 3Active not recruitingPENTA Foundation3862022-04-222026-03-04
INSTI's For The Management of HIV-associated TB
Biktarvy®, TLD- fixed-drug combination single tablet - HIV/AIDS, Tuberculosis, Pulmonary
Phase 2CompletedCentre for the AIDS Programme of Research in South Africa1222022-02-182025-10-03
A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults
GSK3640254, Dolutegravir, Lamivudine capsules - HIV Infections
Phase 2TerminatedViiV Healthcare852021-08-182023-12-14
Pharmacokinetics, Safety, and Efficacy of Dolutegravir Dispersible Tablets in Young Children Living With HIV
DTG DT 20 mg, DTG DT 25 mg - Pediatric HIV Infection
Phase 2UnknownChulalongkorn University302021-08-032021-11-23
Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine
Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato] - HIV Infections
Phase 2CompletedFundacion SEIMC-GESIDA1672021-07-282026-09-09
Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals
Dolutegravir (DTG), Isoniazid (INH), Rifapentine (RPT) - HIV Infection, LTBI
Phase 2TerminatedNational Institute of Allergy and Infectious Diseases (NIAID)372021-02-272024-09-19
A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults
GSK3640254, ABC/3TC, FTC/TAF - HIV Infections
Phase 2TerminatedViiV Healthcare1612020-11-182024-06-26
Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis
Placebo, Dolutegravir 50 mg - HIV Infections, Tuberculosis
Phase 2CompletedUniversity of Cape Town1082019-12-192024-07-18

Showing 20 of 47. Sign in to see all of them.

Conditions studied

HIV Infections (19)  ·  Acquired Immunodeficiency Syndrome (10)  ·  Tuberculosis (5)  ·  Infections (3)  ·  Tuberculosis, Pulmonary (2)  ·  Amyotrophic Lateral Sclerosis (1)  ·  Bone Diseases, Metabolic (1)  ·  Breast Feeding (1)  ·  Gram-Positive Bacterial Infections (1)  ·  HTLV-I Infections (1)  ·  Latent Tuberculosis (1)  ·  Leukemia-Lymphoma, Adult T-Cell (1)  ·  Neuritis (1)  ·  Paraparesis, Tropical Spastic (1)  ·  Weight Gain (1)

Sponsors

ViiV Healthcare (8)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (7)  ·  ANRS, Emerging Infectious Diseases (3)  ·  PENTA Foundation (3)  ·  University of Cape Town (2)  ·  Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1)  ·  Blueclinical, Ltd. (1)  ·  Calmy Alexandra (1)  ·  Carlos Brites (1)  ·  Castagna Antonella (1)  ·  Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida (1)  ·  Centre for the AIDS Programme of Research in South Africa (1)  ·  Chulalongkorn University (1)  ·  Desmond Tutu TB Centre (1)  ·  Federal University of São Paulo (1)

Countries

South Africa (17)  ·  United States (16)  ·  Thailand (10)  ·  Spain (9)  ·  France (7)  ·  Germany (6)  ·  Italy (6)  ·  Uganda (6)  ·  Zimbabwe (6)  ·  Argentina (5)  ·  Brazil (5)  ·  Canada (5)  ·  Portugal (5)  ·  Puerto Rico (4)  ·  Australia (3)

Top investigators

Philip Grant, MD (2)  ·  Adriano Lazzarin, Prof (1)  ·  Adrie Bekker, Prof (1)  ·  Anchalee Avihingsanon, MD, PhD (1)  ·  Andreas Diacon, Prof (1)  ·  Andrew Wiznia, M.D. (1)  ·  Anthony Podany, PharmD (1)  ·  Anushka Naidoo, PhD (1)  ·  Athiporn Premgamone, MD (1)  ·  Babafemi Taiwo, MBBS (1)  ·  Brian P Epling, M.D. (1)  ·  Carlos Brites, MD, PhD (1)  ·  Claire Keene (1)  ·  Delphine Sculier, MD (1)

Results publications

PMID 34817414, PMID 23830355, PMID 24446523, PMID 28219610, PMID 29253097, PMID 29794828, PMID 30601950, PMID 30668695, PMID 31539371, PMID 32408111, PMID 32763217, PMID 33346335, PMID 33446115, PMID 33587897, PMID 33954265, PMID 34670118, PMID 34694878, PMID 34965338, PMID 34996113, PMID 35489377, PMID 35668346, PMID 35868341, PMID 36017341, PMID 36055295, PMID 36356989, PMID 36447613, PMID 36645792, PMID 36706364, PMID 37230101, PMID 37288954, PMID 37766218, PMID 37766505, PMID 38372621, PMID 38568956, PMID 38636725, PMID 39793592, PMID 39972540, PMID 39978387, PMID 41075812, PMID 41344350, PMID 41357330, PMID 41357331, PMID 41467354, PMID 41575190, PMID 41579881, PMID 41665101, PMID 42568101, PMID 42705257, PMID 42731017

NIH funding

2014 (1), 2015 (1), 2017 (1), 2025 (1), 2UM1AI068636 (1), R01AI152142 (1), UM1AI068616 (1), UM1AI068632 (1), UM1AI106716 (1)